Roche NimbleGen introduces enhanced whole exome sequencing solution for medical and translational research

Pleasanton, CA




Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch of the SeqCap EZ MedExome Target Enrichment Kit¹, a comprehensive whole exome sequencing (WES) solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs. 

The release of the SeqCap EZ MedExome Target Enrichment Kit is an example of Roche Sequencing’s commitment to further the evolution of genomic medicine, said Rebecca Selzer, President of Roche NimbleGen. Immense interest in this design from our customers worldwide led to initiation of an early product evaluation process resulting in more than 40 evaluations across 11 countries globally prior to launch. This technology puts some of the most powerful tools of modern genomics to use in more laboratories around the world and is an invaluable asset in furthering the research of disease-associated mutations, while minimizing the need for costly retesting and follow-up sequencing.

Pekka Ellonen, Head of the Sequencing Unit for the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, said, We have evaluated a number of target enrichment systems for whole exome sequencing. The SeqCap EZ MedExome has demonstrated the best on-target read rates and evenness of coverage. Especially the clinically relevant exons are well covered. The protocol is straightforward yet flexible and the overnight hybridization further improves our response time. We are very excited to be an early adopter of this Roche product. For more information about the SeqCap EZ MedExome Kit, visit 

¹For Research Use Only. Not for use in diagnostic procedures. 

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

For further information please contact: 

Roche Sequencing Media Relations
Jacquie Bucher
VP, Marketing and Corporate Communications
Phone: +1 520.468.9145
e-mail: Jacquie Bucher